RYALTRIS (Seqirus Pty Ltd)
Product name
RYALTRIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
168 working days (255)
Active ingredients
olopatadine hydrochloride; mometasone furoate monohydrate
Registration type
EOI
Indication
New Combination
RYALTRIS (nasal spray) is indicated for the treatment of symptoms associated with allergic rhinitis and rhinoconjunctivitis in patients 12 years of age and older.